Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation.

 

For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with its local hospital, the Oncology Institute of Southern Switzerland (IOSI), on innovative new approaches to prostate cancer and lymphoma.

“This collaboration facilitates the seamless transition of lab-based discoveries directly into early clinical trials,” explains IOR Director Andrea Alimonti, who draws on an international career spanning Rome, New York, Boston, and now Ticino.

Unlike many oncology groups focused on a single pathway or tumour type, Alimonti’s team takes a multi-modal approach that bridges basic immunology, tumour biology, and drug engineering. Their work seeks not just to attack cancer cells directly but to reprogramme the tumour microenvironment itself; turning the body’s own defences back on the disease.

Professor Alimonti’s research group has published work in high-impact journals such as Nature and Cancer Cell on tumour immunosuppression, senescence-inducing therapies for prostate cancer, and innovative ways to reprogram myeloid cells to enhance immune responses to therapy.

It is also exploring novel antibody-drug conjugates designed to transform immunologically “cold” tumours into “hot” ones, making them more receptive to immunotherapy.

“Despite being a relatively small institute by global standards with around 150 staff members, we are a significant size within Switzerland and have managed to punch above our weight in terms of scientific output and impact,” he proclaims.

On the other side of the country, Dr Olivier Michielin and his team are leveraging reams of digital data generated at the Geneva University Hospital (HUG) to open new avenues in precision medicine.

“The complete digitalisation of the clinical workflow is enabling pathology to process approximately 1,000 patient slides daily, creating unprecedented opportunities for analysis and artificial intelligence applications,” explains the Harvard-trained Michielin. “This capability provides an optimal environment for both traditional oncology and precision medicine initiatives.”

These efforts extend to working with other institutions; Michielin also serves as clinical coordinator of the recently announced National AI Initiative for Precision Oncology (NAIPO). A multi-stakeholder effort to deploy advanced AI models at every stage of the patient journey, NAIPO aims to optimise diagnostics, personalise treatments, and streamline clinical decision-making in cancer care.

The five-year project is funded with CHF 8.25 million (USD 10.4 million) by Innosuisse, the country’s technology agency, and another CHF 10 million (USD 12.4 million) from partner institutions.

“We are trying to build a collaborative, data-driven intelligence network in oncology, one that connects insights across institutions, systems, and geographies,” explains Jurgi Camblong, founder & CEO of analytics firm and fellow NAIPO partner SOPHiA GENETICS.

Academic institutions are also expanding their industry partnership efforts. At IOR – which is currently adding 12 advanced research laboratories to its campus via a new facility – Alimonti explains that “we collaborate closely with industry, especially in preclinical prostate cancer studies, where we have robust in vitro and in vivo models.”

“Our international lymphoma study group also provides access to rare lymphoma cohorts, attracting pharmaceutical partners eager to explore early-stage drug development,” adds Alimonti, whose institute hosts the annual International Conference on Malignant Lymphoma, the largest lymphoma congress in the world.

He continues, “excitingly, our new facility will deliberately bring academic researchers and entrepreneurs together to create a dynamic ecosystem where scientific discovery and commercial innovation can feed off each other.”

In Geneva, Michielin outlines how HUG has created “multiple complementary mechanisms” for industry collaboration. “Traditional partnerships involve pharmaceutical companies developing compounds that engage with our centres to conduct trials, either directly or through the Swiss Cancer Institute for coordination,” he states.

“Additional innovative collaborations emerge through investigator-initiated trials (IITs), where academic researchers propose new therapeutic strategies or novel applications for existing pharmaceutical compounds, leading to co-development opportunities,” he continues.

“These reverse-innovation partnerships are occurring with increasing frequency and should become more prevalent given their mutual benefits. Additionally, we engage in collaborative data sharing initiatives, combining clinical trial data with additional research datasets to accelerate joint research advancement.”

Solving a healthcare need as complex and devastating as cancer will require broad coalitions of doctors, patients, researchers, and entrepreneurs working together in new and often unusual combinations. Building on its successes thus far, it seems clear that Switzerland – and Swiss science – will have a vital role to play.